The durability of response and survival doubling vs. standard of care significantly de-risks the Phase 3 pathway. With Fast Track status and strong mechanistic validation, CADL is positioned for potential partnership or acquisition interest ahead of Phase 3 initiation. Monitor for upcoming trial design details and potential interim readouts.
Price Chart
Executive Summary
Candel Therapeutics released updated Phase 2a data for its immunotherapy aglatimagene (CAN-2409) in advanced non-small cell lung cancer (NSCLC), showing 50% of patients survived beyond 24 months despite prior inadequate response to immune checkpoint inhibitors. Median overall survival was 25.4 months in the per-protocol population, approximately double historical benchmarks, with strong biomarker evidence of immune activation. The company plans to initiate a pivotal Phase 3 trial in Q2 2026.
Key Facts
- 50% of 46 evaluable NSCLC patients survived beyond 24 months after treatment with aglatimagene plus ICI, up from 39% in prior data cut.
- Median overall survival (mOS) was 25.4 months in per-protocol population, and 21.5 months in patients with progressive disease at baseline — ~2x historical control (9.8–11.8 months).
- 85% of long-term survivors (17/20) had baseline PD-L1 TPS <50%, suggesting ability to convert ICI-resistant tumors.
- Post-treatment biopsies showed increased pro-inflammatory gene expression and TCR repertoire diversity, supporting systemic immune activation.
- FDA has granted Fast Track designation; pivotal Phase 3 trial in non-squamous NSCLC planned for Q2 2026.
Financial Impact
Potential blockbuster-level commercial upside if Phase 3 confirms results, given unmet need in ICI-resistant NSCLC and strong survival tail. No direct financial figures disclosed.
Risk Factors
- Phase 2a data are from a small, non-randomized cohort; results may not replicate in larger, controlled Phase 3 setting.
- Aglatimagene requires intratumoral injection, which may limit scalability and adoption compared to systemic therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers